Evotec (EVO) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
166.4mn → 177.8mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
▲534% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
$1.8M returned vs $−107.7M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
-13¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Over this window: gross 24.5% → 14.5%. Net margin -13.1% is below the sector median.
| Line item | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|
| Revenue & profitability | |||||||
Revenue | 925.2 | 824.9 | 864.4 | 803.9 | 699.5 | ▲12.2% | +7.2% |
Cost of revenue | 791.2 | 706.0 | 670.8 | 617.7 | 528.0 | ▲12.1% | +10.6% |
Gross profit | 134.0 | 118.9 | 193.6 | 186.2 | 171.5 | ▲12.7% | −6.0% |
Research & development | 44.0 | 52.6 | 75.8 | 82.0 | 81.7 | ▼16.4% | −14.3% |
Selling, general & admin | 206.5 | 194.8 | 187.6 | 167.1 | 119.3 | ▲6.0% | +14.7% |
Total operating expenses | 199.3 | 209.6 | 246.2 | 163.9 | 125.1 | ▼4.9% | +12.3% |
Operating incomefeeds ROC rank | −65.2 | −90.7 | −52.6 | 22.3 | 46.4 | ▲28.1% | — |
Other income, net | −36.6 | −110.1 | −36.6 | −187.0 | 221.8 | — | — |
Pretax income | −101.8 | −200.8 | −89.2 | −164.7 | 268.2 | ▲49.3% | — |
Income tax | 19.7 | 2.2 | 3.7 | 23.2 | 24.3 | ▲803.5% | −5.2% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −121.5 | −203.0 | −92.8 | −187.9 | 243.9 | ▲40.1% | — |
| Per share | |||||||
Diluted EPSbuyback-sensitive | −0.68 | −1.14 | −0.52 | −1.06 | 1.47 | ▲40.3% | — |
Diluted shares (mn) | 177.78 | 177.30 | 176.92 | 176.67 | 166.41 | ▲0.3% | +1.7% |
| Margins | |||||||
Gross margin6th pct in Healthcare | 14.5% | 14.4% | 22.4% | 23.2% | 24.5% | ▲0.1pp | −10.0pp |
Operating margin | −7.1% | −11.0% | −6.1% | 2.8% | 6.6% | ▲3.9pp | −13.7pp |
Net margin38th pct in Healthcare | −13.1% | −24.6% | −10.7% | −23.4% | 34.9% | ▲11.5pp | −48.0pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Evotec's revenue last fiscal year?
Evotec reported revenue of $925.2M in fiscal 2025, up 12.2% from fiscal 2024.
What was Evotec's net income?
Evotec reported net income of −$121.5M in fiscal 2025, a net margin of −13.1%.

